BioNTech, DualityBio Breast Cancer Drug Shows Modest Progression-Free Survival Benefit in Phase 3 Trial

Bitget2026/10/26 09:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioNTech and DualityBio reported trastuzumab pamirtecan met the primary endpoint in the Phase 3 DYNASTY-Breast02 trial.
Progression-free survival improved significantly but modestly versus chemotherapy in chemotherapy-naive patients with HR-positive, HER2-low metastatic breast cancer progressing on endocrine therapy.
Interim overall survival data were not yet mature.
Interstitial lung disease occurred more frequently than in earlier studies; most cases were mild or moderate, but some were severe or fatal.
The partners see limited potential benefit relative to available treatments and will review the data to decide next steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioNTech, DualityBio Breast Cancer Drug Shows Modest Progression-Free Survival Benefit in Phase 3 Trial

You may also like

Crypto prices